AVB-500 in combination with cabozantinib - Phase 1/2 Clinical Trial
AVB-500 in combination with cabozantinib - Phase 1/2 Clinical Trial
About This Event
Phase 1b data showed that 46% patients achieved best overall response rate in the ITT population. 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population. 6-month PFS rate in ITT = 79% patients. 6-month PFS rate of 91% in the 15 mg/kg Biomarker High Population. 3-month Duration of Response of 100%, noted March 3, 2022. Phase 2 portion of the study initiated, noted January 31, 2022. Additional data to be presented at the American Association for Cancer Research (AACR) on April 8-13, 2022.
Why This Event Matters
Regulatory milestones can be important for biotech and pharmaceutical names because decisions may affect timelines, labeling, and commercial prospects. Outcomes are uncertain until confirmed by the company or agency materials; this listing is informational. The date shown is April 8, 2022 (America/New_York).
Source summary: Phase 1b data showed that 46% patients achieved best overall response rate in the ITT population. 63% Best Overall Response Rate in the sAXL/GAS6 Biomarker High Population. 6-month PFS rate in ITT = 79% patients. 6-month PFS rate of 91% in the 15 mg/kg Biomarker High Population. 3-month Duration of Response of 100%, noted March 3, 2022. Phase 2 portion of the study initiated, noted January 31,...
This listing is associated with ARAV. Market participants may watch these names around the event window for volatility or news flow.
Frequently Asked Questions
- What is AVB-500 in combination with cabozantinib - Phase 1/2 Clinical Trial?
- It is a stock market catalyst entry on Catacal—an event or release investors and traders may monitor. Details are summarized from the cited source and may be updated over time.
- When is AVB-500 in combination with cabozantinib - Phase 1/2 Clinical Trial?
- The calendar shows Apr 8, 2022 (America/New_York). Verify the exact time and any changes using the source link when planning around the event.
- Why does AVB-500 in combination with cabozantinib - Phase 1/2 Clinical Trial matter for investors?
- Regulatory outcomes can change timelines and risk profiles for drug and device developers.
- Which stocks or sectors could be affected?
- Symbols linked to this listing include ARAV; other names in the same industry group may also move with related news.
- How is this event categorized?
- Catacal groups this entry under "FDA Approval" for navigation. Categories help you find comparable catalysts and build a week-by-week watchlist.
Track Market-Moving Events
Monitor earnings, economic releases, lockups, conferences, and other catalysts that impact stocks.
View Catalyst CalendarComprehensive Calendar
Track earnings, product launches, FDA approvals, economic events, and more.
Impact Ratings
Know which catalysts have the greatest potential to impact stock prices.
Never Miss an Event
Get alerts and reminders so you're always prepared for market-moving events.
View Catalyst Calendar
Track upcoming market events